These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 29176662

  • 1. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
    Norkin M, Katragadda L, Zou F, Xiong S, Chang M, Dai Y, Hsu JW, Moreb JS, Leather H, Murthy HS, Farhadfar N, Li Y, Hromas R, Brown RA, Cogle CR, Wingard JR.
    Blood Cancer J; 2017 Nov 27; 7(12):634. PubMed ID: 29176662
    [Abstract] [Full Text] [Related]

  • 2. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR.
    Best Pract Res Clin Haematol; 2013 Sep 27; 26(3):279-84. PubMed ID: 24309531
    [Abstract] [Full Text] [Related]

  • 3. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
    Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.
    Leukemia; 2016 Jul 27; 30(7):1456-64. PubMed ID: 27012865
    [Abstract] [Full Text] [Related]

  • 4. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JH, Cahn JY, Polge E, Mohty M, Savani BN, Nagler A.
    Am J Hematol; 2018 Sep 27; 93(9):1142-1152. PubMed ID: 29981272
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
    Lucero J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, Stockley T, Gupta V, Bankar A, Chan S, Schuh AC, Minden M, Mattsson J, Kumar R, Sibai H, Tierens A, Kim DDH.
    Ann Hematol; 2024 Apr 27; 103(4):1187-1196. PubMed ID: 38291275
    [Abstract] [Full Text] [Related]

  • 11. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z, Guo M, Zhang Y, Xu S, Cheng H, Wu J, Zhang W, Hu X, Yang J, Wang J, Tang G.
    Int J Lab Hematol; 2019 Oct 27; 41(5):607-614. PubMed ID: 31162830
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M, Perez-Corral A, Martínez-Laperche C, Bento L, Pascual C, Kwon M, Balsalobre P, Muñoz C, Buces E, Serrano D, Gayoso J, Buño I, Anguita J, Diéz-Martín JL.
    Eur J Haematol; 2014 Sep 27; 93(3):239-46. PubMed ID: 24702162
    [Abstract] [Full Text] [Related]

  • 14. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H.
    Cancer; 2017 Feb 01; 123(3):426-435. PubMed ID: 27657543
    [Abstract] [Full Text] [Related]

  • 15. The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
    Nagler A, Dholaria B, Labopin M, Socie G, Huynh A, Itälä-Remes M, Deconinck E, Yakoub-Agha I, Cahn JY, Bourhis JH, Labussière-Wallet H, Chantepie S, Esteve J, Savani B, Mohty M.
    Leukemia; 2020 Apr 01; 34(4):1144-1153. PubMed ID: 31728052
    [Abstract] [Full Text] [Related]

  • 16. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Lu Y, Wu T, Wang H, Zhao YL, Cao XY, Liu DY, Zhang JP, Xiong M, Zhou JR, Sun RJ, Wei ZJ, Ji SQ, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb 14; 38(2):118-123. PubMed ID: 28279035
    [Abstract] [Full Text] [Related]

  • 17. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG.
    J Cancer Res Clin Oncol; 2016 Jan 14; 142(1):317-24. PubMed ID: 26424692
    [Abstract] [Full Text] [Related]

  • 18. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
    Devillier R, Harbi S, Fürst S, Crocchiolo R, El-Cheikh J, Castagna L, Etienne A, Calmels B, Lemarie C, Prebet T, Granata A, Charbonnier A, Rey J, Chabannon C, Faucher C, Vey N, Blaise D.
    Biol Blood Marrow Transplant; 2014 Oct 14; 20(10):1560-5. PubMed ID: 24933658
    [Abstract] [Full Text] [Related]

  • 19. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL.
    Biol Blood Marrow Transplant; 2018 Aug 14; 24(8):1615-1620. PubMed ID: 29684564
    [Abstract] [Full Text] [Related]

  • 20. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
    Nomdedéu JF, Esquirol A, Carricondo M, Pratcorona M, Hoyos M, Garrido A, Rubio M, Bussaglia E, García-Cadenas I, Estivill C, Brunet S, Martino R, Sierra J.
    Biol Blood Marrow Transplant; 2018 Jan 14; 24(1):55-63. PubMed ID: 28939453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.